Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 181 to 195 of 286 results for birth

  1. Are there effective long-term pharmacological interventions to prevent the onset of type 2 diabetes that can be recommended postnatally for women who have been diagnosed with gestational diabetes?

    with gestational diabetes develop type 2 diabetes within 5 years of the birth. There are some data suggesting that changes in diet and...

  2. Transcatheter endovascular closure of perimembranous ventricular septal defect (IPG336)

    Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.

  3. Suspected sepsis: recognition, diagnosis and early management (NG51)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  4. Phrenic nerve transfer in brachial plexus injury (IPG468)

    Evidence-based recommendations on phrenic nerve transfer in brachial plexus injury. This involves finding the phrenic nerve, cutting it and joining it to the damaged nerve in the brachial plexus.

  5. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1)

    This guideline covers diagnosing and managing gastro-oesophageal reflux disease in children and young people (under 18s). It aims to raise awareness of symptoms that need investigating and treating, and to reassure parents and carers that regurgitation is common in infants under 1 year.

  6. Atopic eczema in under 12s: diagnosis and management (CG57)

    This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity.

  7. Melanoma: assessment and management (NG14)

    This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

  8. End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

    This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.

  9. What is the relationship between midwifery staffing and outcomes in maternity settings in England, and what factors act as modifiers or confounders of the relationship between midwifery staffing and outcomes?

    pathway). - Environmental factors (for example, local geography and demography, birth settings and unit size, and physical layout). -...

  10. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

  11. Avalglucosidase alfa for treating Pompe disease (TA821)

    Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.

  12. Postnatal care up to 8 weeks after birth (CG37)

    This guideline has been replaced by NICE guideline NG194.

  13. Healthy start vitamins: special report on cost effectiveness (ECD5)

    Healthy start vitamins: special report on cost effectiveness

  14. Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.

  15. Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

    Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.